Marriott International, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAR research report →
Range $343 – $449
Price Chart
About the company
Marriott International, Inc. is a leading global hospitality firm responsible for managing, franchising, and licensing a wide range of accommodation options, including hotels, residential units, and timeshare resorts, on an international scale. The company segments its extensive operations into North America (covering the U.
- CEO
- Anthony G. Capuano Jr.
- IPO
- 1998
- Employees
- 414,000
- HQ
- Bethesda, MD, US
AI snapshot
Six angles, distilled from the data.
MAR remains in a constructive multi-month uptrend, trading above its 200-day average and 50-day average. The stock sits well below its 52-week high, so the setup is stronger than a full breakout but still short of a stretched momentum regime.
Street sentiment is cautious-to-neutral, with a Hold consensus and 386.71 average target versus a 357.37 share price. Recent calls have leaned mixed: several firms trimmed targets in August and September, while the latest move was a modest raise to $360 from Truist.
The earnings profile is solid, with 6 of the last 7 quarters beating EPS estimates and the most recent quarter topping by 4.2%. Next-year EPS is modeled higher at 13.16 from 9.65 TTM, so shareholders should watch whether Marriott keeps converting revenue growth into another beat.
The signal is mixed but tilted to net selling. The only clear discretionary sales came from the Marriott family group in late September, while most other filings were awards, gifts, or other non-discretionary transfers that carry less trading signal.
Profitability is strong, led by a 65.3% operating margin and 35.0% net margin. Growth is still healthy, with revenue up 11.1% year over year and EPS up 4.3%, while free cash flow reached $3.82 billion on $3.21 billion of operating cash flow.
Marriott’s scale and brand portfolio support premium economics versus most lodging peers, especially with 79.2% gross margin and 14.5% ROE. The valuation is not cheap, at 32.61x earnings, so the market is paying for quality and steadier cash generation.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $92.80B
- P/E
- 37.07
- Fwd P/E
- 30.34
- PEG
- 4.57
- P/S
- 3.45
- P/B
- -21.12
- EV/EBITDA
- 23.35
- Div Yield
- 0.79%
- Gross Margin
- 20.16%
- Op Margin
- 15.80%
- Net Margin
- 9.62%
- ROE
- -66.73%
- ROIC
- 18.61%
Latest fiscal year · YoY change
- Revenue
- $26.19B+4.3%
- Gross Profit
- $5.59B+9.5%
- Op Income
- $4.14B
- Net Income
- $2.60B+9.5%
- EPS
- $9.52+13.9%
- OCF Growth
- +16.8%
- FCF Growth
- +30.5%
- 52W High
- $410.98
- 52W Low
- $256.76
- 50D MA
- $351.90
- 200D MA
- $349.38
- Beta
- 1.10
- RSI (14)
- 56
- Avg Volume
- 1.56M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Marriott delivered a strong Q2 with RevPAR and earnings ahead of expectations, raised full-year guidance, and highlighted robust owner-driven development momentum and new credit card economics.· August 3, 2026
- Q2 global RevPAR rose 3.4%, with U.S. and Canada up 5% and adjusted diluted EPS up 20% to $3.19.
- Gross fee revenues increased 13% to $1.58 billion; adjusted EBITDA rose 13% to $1.59 billion.
- Full-year 2026 global RevPAR guidance was raised to 3% to 3.5%, and adjusted EBITDA guidance was lifted to $5.97 billion to $6.03 billion.
- Net rooms grew 4.5% over the last 12 months, and the pipeline hit a record approximately 629,000 rooms.
- New U.S. co-brand card agreements are expected to add about $30 million in 2026 and build toward $100 million to $125 million of annual fee impact by 2028 at the current royalty rate.
Marriott reported second-quarter 2026 gross fee revenues of $1.58 billion, up 13% year over year. Adjusted diluted EPS was $3.19, up 20%, and adjusted EBITDA was $1.59 billion, up 13%. Global RevPAR rose 3.4%; U.S. and Canada RevPAR rose 5%, international RevPAR declined slightly, EMEA RevPAR declined just over 5%, APEC RevPAR rose over 5%, Greater China RevPAR rose over 3%, and CALA RevPAR rose 3%. For full-year 2026, management raised global RevPAR guidance to 3% to 3.5%, gross fee revenue to $6.03 billion to $6.06 billion, adjusted EBITDA to $5.97 billion to $6.03 billion, and adjusted diluted EPS growth to 16% to 18%. Third-quarter global RevPAR is expected to rise 3.5% to 4%, and third-quarter adjusted EBITDA is expected to increase 7% to 9%.
Tony Capuano framed the quarter as broad-based and better than expected, emphasizing strong demand in the U.S. and Canada, resilient luxury and leisure trends, and improving momentum in APEC and Greater China. He spent much of his remarks on owner economics and development: lower loyalty charge-out rates, enhanced reimbursement on redemption stays, streamlined brand standards, and the planned ITR incentive were all presented as ways to support owners while reinforcing Marriott’s long-term growth engine. He also highlighted record first-half signings, a record pipeline, and technology initiatives including Ask Bonvoy and broader AI deployment, all in a confident but pragmatic tone.
Jen Mason focused on the financial bridge: gross fee revenues were up 13% to $1.58 billion, IMF rose 6% to $212 million, adjusted EBITDA increased 13% to $1.59 billion, and adjusted diluted EPS rose to $3.19. She raised 2026 gross fee guidance to $6.03 billion to $6.06 billion, adjusted EBITDA to $5.97 billion to $6.03 billion, and investment spending to $1.25 billion to $1.35 billion. She also quantified the new co-brand contribution as about $30 million in 2026 from two quarters of the new U.S. terms, noted full-year credit card fees are expected to rise in the high 30% range, and said 2026 shareholder returns are expected to exceed $4.5 billion.
Analysts pressed on how Marriott is reinvesting in owners, especially the new ITR incentive, and Mason said the program launches this week with reimbursement of up to 50 basis points of gross room revenue for qualifying hotels. Questions also focused on the new co-brand economics, where Capuano said the $30 million 2026 benefit is only a partial-year effect and that the annual impact could reach $100 million to $125 million by full year 2028 at a 26% royalty rate. Other topics included Middle East drag, net rooms growth, and 2027 visibility; management said Middle East disruption is the main reason net rooms guidance is near the low end of the prior range, but signings and pipeline momentum remain strong, with no sign of weakening owner appetite.
The call painted a picture of durable demand, with RevPAR up across most regions and management saying broad-based strength in rate and demand could continue into 2027. Marriott also pointed to record signings, a record pipeline, and stronger developer interest in conversions, suggesting the growth runway remains intact. New co-brand agreements, AI-enabled tools, and owner-friendly changes like ITR and lower loyalty charge-out rates add additional upside levers.
The biggest headwind remains the Middle East conflict, which cut EMEA performance and is still expected to weigh on full-year RevPAR and net rooms growth. Management also flagged a tougher fourth quarter because the Middle East has a heavier seasonal impact then and faces difficult comparisons, while U.S. benefit from World Cup demand will fade. On top of that, Marriott is spending more on renovations, tech, and incentives to owners, and the owner relationship issue remains active enough that management repeatedly emphasized ongoing discussions and P&L impact from those talks.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.6%
- Shares Outstanding
- 260.77M
- Float Shares
- 225.70M
of shares held by institutions
1,709 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MAR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Val HoyleHouse · OR04 | Sell | Sep 23, 25 | Filing → |
| Michael T. McCaulHouse · TX10 | — | Mar 25, 24 | Filing → |
| Val HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Susie LeeHouse · NV03 | Sell | Mar 14, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 9, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Aug 2, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jul 9, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jun 28, 24 | Filing → |
| Josh S. GottheimerHouse · NJ05 | Sell | Jun 7, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 14, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Sell | May 3, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 20.68M | ▼ 93.88K |
| Blackrock, Inc. | 16.05M | ▲ 558.47K |
| Vanguard Capital Management LLC | 14.04M | ▲ 5.45K |
| State Street Corp | 9.64M | ▲ 272.04K |
| Invesco Ltd. | 9.64M | ▲ 4.08M |
| Fmr LLC | 6.81M | ▼ 265.30K |
| Wellington Management Group Llp | 5.47M | ▼ 374.58K |
| Geode Capital Management, LLC | 5.35M | ▲ 41.15K |
| Morgan Stanley | 4.98M | ▲ 278.69K |
| Jpmorgan Chase & Co | 4.10M | ▲ 1.04M |
| Vanguard Portfolio Management LLC | 4.04M | ▼ 169.91K |
| Massachusetts Financial Services Co | 3.71M | ▼ 552.53K |
Held by 1,876 ETFs
Biggest fund positions in MAR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Reid Grant | other | 69.507 |
| Sep 30, 26 | LEWIS AYLWIN B | other | 10.079 |
| Sep 25, 26 | Marriott David S | sell | 3,500 |
| Sep 25, 26 | Harrison Deborah Marriott | sell | 3,500 |
| Sep 25, 26 | MARRIOTT J W JR | sell | 3,500 |
| Sep 8, 26 | Marriott David S | other | 2,000,000 |
| Sep 8, 26 | Harrison Deborah Marriott | other | 2,000,000 |
| Sep 8, 26 | Juliana B. Marriott Marital Trust | other | 2,000,000 |
| Sep 8, 26 | Marriott Juliana B. | other | 2,000,000 |
| Aug 17, 26 | Jones Neal | other | 107 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MAR coverage
Recent articles, reports, and earnings notes.

Marriott International (MAR): Fee Growth Meets Leverage Risk
Marriott delivered 17% adjusted EPS growth and 4.2% global RevPAR gains, supported by a nearly 618,000-room development pipeline. The Buy case is strong, but leverage and a rich valuation keep the risk profile elevated.

Marriott's EPS beat is hiding the demand problem
Marriott's latest EPS beat cannot conceal a top-line story that is too soft for a premium valuation. With revenue growth at 4.3%, fragile U.S. travel demand and a stock already breaking below key moving averages, the risk remains skewed lower into Q3.

Hotels and Resorts Stocks That Reward Quality: 5 Picks for August 2026
Five hotels and resorts stocks are ranked by investment quality, with franchising economics, margins, valuation, and earnings consistency in focus.
Want a deeper read on MAR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
The Rise of Place: Marriott International Reveals Asia Pacific's Future of Food
prnewswire.com · Oct 6
THE RITZ-CARLTON NAPLES, TIBURÓN REVEALS TRANSFORMED RESORT AND DYNAMIC CULINARY CONCEPTS
prnewswire.com · Oct 5
Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
proactiveinvestors.com · Oct 5
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
globenewswire.com · Oct 5
Forget Inflation: Funflation Is Here and These ETFs Are Riding on It
zacks.com · Sep 28
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
globenewswire.com · Sep 24
Allworth Financial LP Has $5.55 Million Stock Holdings in Marriott International, Inc. $MAR
defenseworld.net · Sep 10
Marriott International, Inc. (MAR) Presents at Bank of America Gaming and Lodging Conference 2026 Transcript
seekingalpha.com · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed October 2, 2026 · Live quote · Not investment advice